Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489912 | 0.90 | LMNA (0.52) | MAPTLMNAKDM4EHSD17B10HPGD | |
| SCHEMBL5489041 | 0.90 | LMNA (0.52) | MAPTLMNAKDM4EHSD17B10HPGD | |
| SCHEMBL7438219 | 0.89 | MAPT (0.67) | MAPTLMNAKDM4EHSD17B10HPGD | |
| SCHEMBL5492977 | 0.89 | MAPT (0.77) | MAPTLMNAKDM4EHSD17B10HPGD | |
| SCHEMBL4851027 | 0.87 | MAPT (0.54) | MAPTLMNAKDM4EHSD17B10HPGD | |
| SCHEMBL4543074 | 0.86 | MAPT (0.63) | MAPTLMNAKDM4EHSD17B10HPGD | |
| SCHEMBL2394192 | 0.85 | POLB (0.60) | MAPTLMNAKDM4EHPGDHTT | |
| SCHEMBL5490882 | 0.85 | MAPT (0.59) | MAPTLMNAKDM4EHPGDCYP3A4 | |
| SCHEMBL7296709 | 0.85 | KDM4E (0.54) | MAPTLMNAKDM4EHSD17B10HPGD | |
| SCHEMBL2605631 | 0.85 | KDM4E (0.71) | LMNAKDM4EHSD17B10CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556055-B1 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY | VIA PHARMACEUTICALS INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | disclosed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
| EP-0109624-A2 | Process for producing shaped articles made from polyurethane-polyurea which may be cellular | BASF Aktiengesellschaft (DE) | 1984-05-30 | — | — | EP | disclosed |
| US-4313872-A | MONDAZO AND DISAZO DYES | CASSELLA AKTIENGESELLSCHAFT (DE) | 1982-02-02 | — | — | US | disclosed |
| US-4118384-A | DIAZOTIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | PDE7A, PDE4A, PDE4B | MAPT 3649/4885LMNA 2259/4885KDM4E 2333/4885 |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | MAPT 4388/4885LMNA 1410/4885KDM4E 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.